Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 23Unspecified Adult Solid Tumor, Protocol Specific 14Urinary Bladder Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 9Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms 6Adenocarcinoma of Lung 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Follicular 5Carcinoma, Ovarian Epithelial 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Colonic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Neoplasms 3

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Bladder Urothelial Carcinoma × Gemcitabine × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡